Amgen Inc. sued Novartis AG’s Sandoz in New Jersey federal court Monday, accusing Sandoz’s proposed versions of its multibillion-dollar bone-strengthening drugs Prolia and Xgeva of infringing several patents.

The year 2022 was relatively thin for pharma M&A, with deals worth nearly $66 billion being announced by early December. However, drugmakers are primed for a shopping spree in 2023.